---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-073430"
form_type: "8-K"
ticker: "SNGX"
cik: "0000812796"
company_name: "SOLIGENIX, INC."
filed_at: "2026-06-12T20:05:59+00:00"
generated_at: "2026-06-12T20:17:21.529818+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Soligenix terminates HyBryte program after Phase 3 futility; receives Nasdaq bid price deficiency notice

## Summary
- Received Nasdaq notice for non-compliance with $1.00 minimum bid price; 180 days until Dec 7, 2026 to regain compliance.
- Board terminated HyBryte (synthetic hypericin) development program after DMC recommended halt for futility.
- Expected wind-down charges of approximately $70,000 from closing FLASH2 trial.
- Consulting CMO Richard Straube stepped down; duties transitioned to Medical Director Christopher Pullion.
- Company will evaluate strategic alternatives including M&A and advancing dusquetide (SGX945) for Behçet's Disease.

## SEC filing metadata
- accession: 0001104659-26-073430
- form_type: 8-K
- ticker: SNGX
- cik: 0000812796
- company_name: SOLIGENIX, INC.
- filed_at: 2026-06-12T20:05:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/812796/000110465926073430/0001104659-26-073430-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/812796/000110465926073430/sngx-20260610x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-073430
- JSON: https://secwatch.observer/filing/0001104659-26-073430.json
- Plain text: https://secwatch.observer/filing/0001104659-26-073430.txt

## Key facts
- Listing & Compliance Notices
  SOLIGENIX, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: June 10, 2026, Soligenix, Inc. (the “Company”) received a written notice (the “Bid Price Notice”) from the Listing Qualifications department (the “Nasdaq Staff”) of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market under the symbol “SNGX,” and the Company is currently monitoring th
  evidence_url: https://www.sec.gov/Archives/edgar/data/812796/000110465926073430/0001104659-26-073430-index.htm
- Executive change
  Richard C. Straube departed as Consulting Chief Medical Officer at SOLIGENIX, INC..
  - Action: ceased serving
  - Role: Consulting Chief Medical Officer
  source text: Dr. Straube ceased serving as the Company's Consulting Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/812796/000110465926073430/0001104659-26-073430-index.htm
- Executive change
  Christopher Pullion changed role as Medical Director at SOLIGENIX, INC..
  - Action: transitioned responsibilities
  - Role: Medical Director
  source text: Dr. Straube's responsibilities will be transitioned to Dr. Christopher Pullion, the Company's Medical Director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/812796/000110465926073430/0001104659-26-073430-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.